Related Experiment Video
Updated: Aug 5, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
A Case of Elderly-Onset Ulcerative Colitis with Large-Vessel Giant Cell Arteritis Treated Successfully with
Kotaro Mitsui1, Yoh Ishiguro1, Naoki Higuchi1
1Department of Gastroenterology, NHO Hirosaki General Medical Center, Hirosaki, Japan.
Insights
Giant cell arteritis (GCA) can manifest in ulcerative colitis (UC) patients. This case shows tofacitinib may help manage GCA and UC overlap, potentially leading to steroid-free remission.
Area of Science:
- Vascular Inflammation
- Gastroenterology
- Rheumatology
Background:
- Large-vessel vasculitis, including giant cell arteritis (GCA), is an extraintestinal manifestation of ulcerative colitis (UC).
- Optimal management strategies for this overlap syndrome remain unclear.
- GCA predominantly affects individuals over 50 and can involve large arteries.
Introduction:
Large-vessel vasculitis, including Takayasu arteritis and giant cell arteritis (GCA), is a recognized extraintestinal manifestation of ulcerative colitis (UC), but its optimal management remains unclear. GCA is the principal systemic vasculitis in individuals aged over 50 years, and large-vessel involvement may occur with or without cranial disease. We report a case of UC complicated by inflammation of the thoracic aorta and the proximal left subclavian and brachiocephalic arteries.
Case Presentation:
A 78-year-old man was diagnosed with proctitis-type UC. Mesalamine was switched to rectal budesonide enema plus azathioprine owing to intolerance. One month later, fever and neck pain appeared. Continuous linear hyperintensity on T2-weighted magnetic resonance imaging extended from part of the ascending aorta through the descending aorta, involving the aortic arch and the proximal left subclavian and brachiocephalic arteries and becoming less conspicuous distally. Corresponding images of contrast-enhanced T1-weighted sampling perfection with application-optimized contrasts using different flip-angle evolutions with spectral pre-saturation with inversion recovery demonstrated matching mural enhancement, consistent with large-vessel GCA. Tocilizumab was administered, but UC relapsed, prompting adalimumab initiation, which later resulted in loss of response. Infliximab was attempted but was discontinued because of an infusion reaction. Prednisolone 10 mg/day resulted in improvement, and tofacitinib was introduced for steroid tapering.
Conclusion:
This case highlights the importance of considering large-vessel GCA in elderly-onset UC with unexplained fever and demonstrates the potential role of tofacitinib in achieving steroid-free remission and vascular inflammation, offering a potential novel therapeutic option for refractory overlap syndromes.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...